PT  - JOURNAL ARTICLE
AU  - Bai, Benjamin Y. H.
AU  - Reppell, Mark
AU  - Smaoui, Nizar
AU  - Waring, Jeffery F.
AU  - Pivorunas, Valerie
AU  - Guay, Heath
AU  - Lin, Simeng
AU  - Chanchlani, Neil
AU  - Bewshea, Claire
AU  - Goodhand, James R.
AU - UK Inflammatory Bowel Disease Pharmacogenetics Study Group
AU  - Kennedy, Nicholas A.
AU  - Ahmad, Tariq
AU  - Anderson, Carl A.
TI  - Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn’s disease patients
AID  - 10.1101/2023.04.19.23288234
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.19.23288234
4099  - http://medrxiv.org/content/early/2023/04/24/2023.04.19.23288234.short
4100  - http://medrxiv.org/content/early/2023/04/24/2023.04.19.23288234.full
AB  - Background and Aims Anti-TNF therapy is widely used for treatment of inflammatory bowel disease (IBD), yet many patients are primary non-responders (PNR), failing to respond to induction therapy. We aimed to identify blood gene expression differences between primary responders (PR) and primary non-responders to anti-TNF monoclonal antibodies (infliximab and adalimumab); and to predict response status from blood gene expression and clinical data.Methods The Personalised Anti-TNF Therapy in Crohn’s Disease (PANTS) study is a UK-wide prospective observational cohort study of anti-TNF therapy outcome in anti-TNF naive Crohn’s disease (CD) patients (ClinicalTrials.gov identifier: NCT03088449). Blood gene expression in 324 unique patients was measured by RNA-seq at baseline (week 0), and at weeks 14, 30, and 54 after treatment initiation (total sample size = 814).Results After adjusting for clinical covariates and estimated blood cell composition, baseline expression of MHC, antigen presentation, myeloid cell enriched receptor, and other innate immune gene modules was significantly higher in anti-TNF responders. Expression changes from baseline to week 14 were generally of consistent direction across patients but with greater magnitude in responders, with the exception of interferon-related genes that were upregulated uniquely in non-responders. Expression differences between responders and non-responders observed at week 14 were maintained at week 30 and week 54. Prediction of response status from baseline clinical data, cell composition, and module expression was poor.Conclusions Baseline gene module expression was associated with primary response to anti-TNF therapy in PANTS patients. However, these expression differences were insufficient for clinically useful prediction of response.Competing Interest StatementMark Reppell, Nizar Smaoui, Jeffery F. Waring, Valerie Pivorunas, and Heath Guay are employees of AbbVie and may own stock and/or options. Simeng Lin reports non-financial support from Pfizer outside the submitted work. James R. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik outside the conduct of the study. Nicholas A. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik; grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, and personal fees and non-financial support from Dr Falk, outside the submitted work. Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik; personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech and non-financial support from Tillotts, outside the submitted work. Carl A. Anderson has received consultancy or lectureship fees from Genomics plc, BridgeBio, and GSK. The remaining authors have no conflicts of interest to report.Clinical Protocols https://www.ibdresearch.co.uk/pants/ Funding StatementPANTS is an investigator-led study funded by CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology, and by unrestricted educational grants from AbbVie Inc, USA, Merck Sharp & Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer Ltd, USA, Celltrion Healthcare, South Korea, and Cure Crohn's Colitis (Scottish IBD Charity). The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service Foundation Trust. Data generation, sequencing, and sample analysis were funded by AbbVie. This research was funded in whole, or in part, by the Wellcome Trust [grant numbers 206194, 108413/A/15/D, and 222850/Z/21/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South West Research Ethics committee approved the study (Research Ethics Committee reference: 12/SW/0323) in January 2013. Patients were included after providing informed, written consent. The study is registered with ClinicalTrials.gov identifier NCT03088449, and the protocol is available at https://www.ibdresearch.co.uk/pants/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual participant de-identified data that underlie the results reported in this article will be available immediately after publication for a period of 5 years. The data will be made available to investigators whose proposed use of the data has been approved by an independent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to Tariq Ahmad (tariq.ahmad1{at}nhs.net) and Carl A. Anderson (ca3{at}sanger.ac.uk). To gain access data requestors will need to sign a data access agreement.ADAadalimumabAICAkaike information criterionBMIbody mass indexBTMsblood transcriptomic modulesCDCrohn’s diseaseCRPC-reactive proteinFDRfalse discovery rateIBDinflammatory bowel diseaseIFXinfliximabIMIDimmune-mediated inflammatory diseaseLORloss of responsePANTSPersonalised Anti-TNF Therapy in Crohn’s DiseasePNRprimary non-response/non-responderPRprimary response/responderTNFtumour necrosis factorUCulcerative colitisrRNAribosomal RNAssGSEAsingle-sample gene set enrichment score